Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 11/20 | 0.40 |
| ▸ | IDH1 | O75874 | 6/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19687060 | 0.87 | GABRA1 (0.40) | GABRA1IDH1ROCK2NNMT | |
| SCHEMBL21143787 | 0.85 | IDH1 (0.41) | IDH1ROCK2CD38 | |
| SCHEMBL31127174 | 0.81 | IDH1 (0.44) | IDH1 | |
| SCHEMBL21143933 | 0.81 | IDH1 (0.44) | IDH1 | |
| SCHEMBL21165977 | 0.80 | IDH1 (0.37) | IDH1 | |
| SCHEMBL31127071 | 0.79 | IDH1 (0.46) | IDH1 | |
| SCHEMBL21144172 | 0.79 | IDH1 (0.46) | IDH1 | |
| SCHEMBL21143854 | 0.79 | IDH1 (0.46) | IDH1 | |
| SCHEMBL31127082 | 0.79 | IDH1 (0.46) | IDH1 | |
| SCHEMBL21165901 | 0.79 | IDH1 (0.41) | IDH1CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | GABRA1 325/4885IDH1 3017/4885ROCK2 3705/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | GABRA1 325/4885IDH1 3017/4885ROCK2 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.